Form D · Biotechnology
CALOSYN PHARMA, INC.
Shreveport, LA · CIK 0001429819
Offering snapshot reported Mar 7, 2024 · SEC filing
- Reported sold
- $750K Offering amount: $2M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 22, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 7, 2024 | Initial | $750,000 | No comparison | 7 | SEC filing |
| Feb 29, 2012 | Initial | $309,685 | No comparison | 3 | SEC filing |
| Apr 13, 2010 | Amendment | $1,863,392 | $1,463,392vs Apr 13, 2009 | 5 | SEC filing |
| Apr 13, 2009 | Initial | $400,000 | No comparison | Not reported | SEC filing |
| Mar 12, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-507011
Source: Form D, filed Mar 7, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Babb | Director, Executive |
| Ross P. Barrett | Director, Executive |
| Martin Becker | Director, Executive |
| William R. Grimes | Director, Executive |
| Joseph Lovett | Director |
| Mike Sherman | Director |
| Stephen Snowdy | Director, Executive |
| David P. Waddell | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2031 Kings Highway
Shreveport, LA, 71103
Shreveport, LA, 71103